Results 11 to 20 of about 13,727 (197)

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure
There is a need to address the evidence gap regarding the in‐hospital administration of sacubitril/valsartan in acute myocardial infarction patients.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
doaj   +2 more sources

Sacubitril/Valsartan [PDF]

Hospital Pharmacy, 2015
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada, Danial E, Baker, James, Leonard   +2 more
openaire   +2 more sources

Sacubitril–valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis

Frontiers in Pharmacology, 2023
Background: The episode of acute decompensated heart failure (ADHF) is the main cause of hospitalization for heart failure (HF). Sacubitril–valsartan has been proven to be effective in reducing the risks of hospitalization for HF in ADHF.
Tianyang Hu, Yiting Liu, Yake Lou
doaj   +1 more source

Sacubitril/Valsartan Initiation Among Veterans Who Are Renin‐Angiotensin‐Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Sacubitril/valsartan, a first‐in‐class angiotensin receptor neprilysin inhibitor, received US Food and Drug Administration approval in 2015 for heart failure with reduced ejection fraction (HFrEF).
April F. Mohanty, Emily B. Levitan, Jordan B. King, John A. Dodson, Orly Vardeny, James Cook, Jennifer S. Herrick, Tao He, Olga V. Patterson, Patrick R. Alba, Patricia A. Russo, Engels N. Obi, Michelle E. Choi, James C. Fang, Adam P. Bress   +14 more
doaj   +1 more source

Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure [PDF]

, 2018
Objectives: The purpose of this study was to evaluate the renal effects of sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
Claggett, Brian, Damman, Kevin, Desai, Akshay S., Gori, Mauro, Jhund, Pardeep S., Lefkowitz, Martin P., McMurray, John J.V., Packer, Milton, Prescott, Margaret F., Rouleau, Jean L., Senni, Michele, Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +14 more
core   +9 more sources

Effect of Sacubitril-Valsartan on Restoration and Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation

Frontiers in Cardiovascular Medicine, 2022
BackgroundExisting studies have shown that sacubitril-valsartan ameliorated atrial remodeling in atrial fibrillation (AF) and favored maintenance of sinus rhythm in patients with AF and heart failure.
Qingsong Chen, Yunlin Chen, Fang Qin, Huaan Du, Chunxia Gan, Bei Zhou, Na Wang, Mingyang Xiao, Zhenhong Ou, Wei Zhao, Ben Cui, Zengzhang Liu, Yuehui Yin   +12 more
doaj   +1 more source

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Sacubitril/Valsartan has been highly efficacious in randomized trials of heart failure with reduced ejection fraction (HFrEF). However, the effectiveness of sacubitril/valsartan in older patients hospitalized for HFrEF in real‐world US ...
Stephen J. Greene, Sujung Choi, Steven J. Lippmann, Robert J. Mentz, Melissa A. Greiner, N. Chantelle Hardy, Bradley G. Hammill, Nancy Luo, Marc D. Samsky, Paul A. Heidenreich, Warren K. Laskey, Clyde W. Yancy, Pamela N. Peterson, Lesley H. Curtis, Adrian F. Hernandez, Gregg C. Fonarow, Emily C. O'Brien   +16 more
doaj   +1 more source

Sacubitril/Valsartan and Ivabradine Attenuate Left Ventricular Remodelling and Dysfunction in Spontaneously Hypertensive Rats: Different Interactions with the Renin–Angiotensin–Aldosterone System

Biomedicines, 2022
This study investigated whether sacubitril/valsartan and ivabradine are able to prevent left ventricular (LV) fibrotic remodelling and dysfunction in a rat experimental model of spontaneous hypertension (spontaneously hypertensive rats, SHRs) and whether
Fedor Simko, Tomas Baka, Peter Stanko, Kristina Repova, Kristina Krajcirovicova, Silvia Aziriova, Oliver Domenig, Stefan Zorad, Michaela Adamcova, Ludovit Paulis   +9 more
doaj   +1 more source

Sacubitril-Valsartan

Reactions Weekly
Patel P, Nicolas D, Reed M.
europepmc   +8 more sources

Resetting the neurohormonal balance in heart failure (HF). the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF [PDF]

, 2017
The natriuretic peptide (NP) system, which includes atrial natriuretic peptide, B-type natriuretic peptide, and C-type natriuretic peptide, has an important role in cardiovascular homeostasis, promoting a number of physiological effects including ...
Rubattu, Speranza Donatella, Triposkiadis, Filippos   +1 more
core   +2 more sources